Neoadjuvant therapy for bladder cancer with active surveillance
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests whether people with muscle-invasive bladder cancer can safely avoid immediate surgery or radiation after a short course of chemotherapy. Instead, they would be closely monitored and only treated if the cancer comes back.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older.
- You have bladder cancer that has grown into the muscle layer (stage T2-T4a) but has not spread to lymph nodes or other organs.
- You have not had any chemotherapy or immunotherapy for bladder cancer before.
- You are healthy enough to possibly have surgery or radiation, and you can have an MRI of your pelvis.
- You have not had another cancer (except for certain low-risk ones) in the last 5 years.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 study tests whether adding chemotherapy and immunotherapy along with targeted pelvic radiation after bladder tumor surgery can reduce bladder cancer returning or spreading. It focuses on people with non-metastatic, muscle-invasive urothelial bladder cancer.
This trial tests a bladder-sparing approach for people with muscle-invasive bladder cancer that has a variant histology type. The goal is to avoid removing the bladder by using a combination of treatments.
This trial tests a combination of two drugs (enfortumab vedotin and pembrolizumab) plus radiation therapy for people with bladder cancer that has grown into the muscle layer. The goal is to see if this treatment can kill the cancer while avoiding the need for bladder removal surgery.
This study compares two approaches for people with early-stage bladder cancer that has a low chance of coming back: either careful monitoring without immediate treatment, or receiving chemotherapy directly into the bladder to lower the risk of recurrence. It aims to see if monitoring alone is as good as chemotherapy for those with a low risk detected by a urine test.
This study looks at how well a standard chemotherapy given before surgery works for muscle-invasive bladder cancer. It aims to see if higher responses lead to better outcomes.
This study follows people with muscle-invasive bladder cancer who choose to keep their bladder (instead of removing it) after receiving chemotherapy, immunotherapy, or an ADC drug. It aims to see how well this approach works and what side effects may occur.
Hear when a new Muscle-Invasive Bladder Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.